Bayer urges rebellion against NICE no for Sativex
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, has released new guidelines for the diagnosis and treatment of multiple sclerosis patients, in which it has rejected GW Pharmaceuticals' Sativex and Biogen Idec's Fampyra, both drugs derived from cannabis. But Bayer, a licensee of Sativex, has urged UK prescribers to ignore the guidelines and continue to prescribe Sativex.